Novo Nordisk

Novo Nordisk’s September Reckoning: A Raised Forecast That Failed to Soothe

Brett Shapiro -

Novo Nordisk’s Pipeline Setbacks Test the Patience of Investors Ahead of Earnings

Brett Shapiro -

Novo Nordisk’s Big Test: Can a Mass-Market Reality Replace the Miracle-Stock Narrative?

Brett Shapiro -

Novo Nordisk’s August Reckoning: A Failed Heart Drug, a Depressed Valuation, and Earnings That Could Go Either Way

kashif hafeez -

Novo Nordisk’s Legal and Commercial Offensive Faces a Generics Countdown

Novo Nordisk’s Twin Regulatory Wins Mask a Technical Pause as CagriSema Data Looms

kashif hafeez -

Novo Nordisk Taps Indian Manufacturer to Feed Wegovy Demand as Medicare Opens Door, But Overbought Signals Warn of Pullback

Brett Shapiro -

Novo Nordisk’s Two-Front War: Oral Wegovy Surges as CagriSema Awaits FDA Verdict

angelina -

Novo Nordisk’s Medicare Opening and Hemophilia Data Readout Set Up a Defining Summer

Brett Shapiro -

Novo Nordisk’s Twin Catalysts: Medicare Bridge and UK Oral Wegovy Launch in Rapid Succession

angelina -

Novo Nordisk Navigates a Pivotal Summer: Medicare Access, Pipeline Milestones, and Cyberattack Fallout

Brett Shapiro -

Novo Nordisk Fights on Two Fronts: Cyber Criminals and Copycat Drugs, as Shares Recover

Novo Nordisk’s Pill Boom Hits 3 Million Scripts as a €69 Million Research Blitz Backs the Next Frontier

angelina -

Novo Nordisk Shrugs Off $25 Million Ransomware Threat as Wegovy Expands in Japan and Pills Hit 3 Million Scripts

angelina -

Novo Nordisk’s Pipeline Gains Traction as Zenagamtide Data and CagriSema Filing Drive Investor Focus

kashif hafeez -
1234Page 1 of 4